Search

Your search keyword '"Wagenaar, L J"' showing total 24 results
Start Over Author "Wagenaar, L J"
24 results on '"Wagenaar, L J"'

1. The first multicentre study on coronary anomalies in the Netherlands: MuSCAT

Author

Koppel, C. J., Driesen, B. W., de Winter, R. J., van den Bosch, A. E., van Kimmenade, R., Wagenaar, L. J., Jukema, J. W., Hazekamp, M. G., van der Kley, F., Jongbloed, M. R. M., Kiès, P., Egorova, A. D., Verheijen, D. B. H., Damman, P., Schoof, P. H., Wilschut, J., Stoel, M., Speekenbrink, R. G. H., Voskuil, M., and Vliegen, H. W.

Published
2021
Full Text
View/download PDF

5. The first multicentre study on coronary anomalies in the Netherlands:MuSCAT

Author

Koppel, C. J., Driesen, B. W., de Winter, R. J., van den Bosch, A. E., van Kimmenade, R., Wagenaar, L. J., Jukema, J. W., Hazekamp, M. G., van der Kley, F., Jongbloed, M. R.M., Kiès, P., Egorova, A. D., Verheijen, D.B.H., Damman, P., Schoof, P. H., Wilschut, J., Stoel, M., Speekenbrink, R. G.H., Voskuil, M., Vliegen, H. W., Koppel, C. J., Driesen, B. W., de Winter, R. J., van den Bosch, A. E., van Kimmenade, R., Wagenaar, L. J., Jukema, J. W., Hazekamp, M. G., van der Kley, F., Jongbloed, M. R.M., Kiès, P., Egorova, A. D., Verheijen, D.B.H., Damman, P., Schoof, P. H., Wilschut, J., Stoel, M., Speekenbrink, R. G.H., Voskuil, M., and Vliegen, H. W.

Abstract

Background: Current guidelines on coronary anomalies are primarily based on expert consensus and a limited number of trials. A gold standard for diagnosis and a consensus on the treatment strategy in this patient group are lacking, especially for patients with an anomalous origin of a coronary artery from the opposite sinus of Valsalva (ACAOS) with an interarterial course. Aim: To provide evidence-substantiated recommendations for diagnostic work-up, treatment and follow-up of patients with anomalous coronary arteries. Methods: A clinical care pathway for patients with ACAOS was established by six Dutch centres. Prospectively included patients undergo work-up according to protocol using computed tomography (CT) angiography, ischaemia detection, echocardiography and coronary angiography with intracoronary measurements to assess anatomical and physiological characteristics of the ACAOS. Surgical and functional follow-up results are evaluated by CT angiography, ischaemia detection and a quality-of-life questionnaire. Patient inclusion for the first multicentre study on coronary anomalies in the Netherlands started in 2020 and will continue for at least 3 years with a minimum of 2 years of follow-up. For patients with a right or left coronary artery originating from the pulmonary artery and coronary arteriovenous fistulas a registry is maintained. Results: Primary outcomes are: (cardiac) death, myocardial ischaemia attributable to the ACAOS, re-intervention after surgery and intervention after initially conservative treatment. The influence of work-up examinations on treatment choice is also evaluated. Conclusions: Structural evidence for the appropriate management of patients with coronary anomalies, especially (interarterial) ACAOS, is lacking. By means of a structured care pathway in a multicentre setting, we aim to provide an evidence-based strategy for the diagnostic evaluation and treatment of this patient group.

Published
2021

6. The first multicentre study on coronary anomalies in the Netherlands: MuSCAT

Author

Cardiologie onderzoek 2, Cardiopulmonale Chirurgie pat. zorg, Child Health, Team Medisch, Circulatory Health, Koppel, C J, Driesen, B W, de Winter, R J, van den Bosch, A E, van Kimmenade, R, Wagenaar, L J, Jukema, J W, Hazekamp, M G, van der Kley, F, Jongbloed, M R M, Kiès, P, Egorova, A D, Verheijen, D B H, Damman, P, Schoof, P H, Wilschut, J, Stoel, M, Speekenbrink, R G H, Voskuil, M, Vliegen, H W, Cardiologie onderzoek 2, Cardiopulmonale Chirurgie pat. zorg, Child Health, Team Medisch, Circulatory Health, Koppel, C J, Driesen, B W, de Winter, R J, van den Bosch, A E, van Kimmenade, R, Wagenaar, L J, Jukema, J W, Hazekamp, M G, van der Kley, F, Jongbloed, M R M, Kiès, P, Egorova, A D, Verheijen, D B H, Damman, P, Schoof, P H, Wilschut, J, Stoel, M, Speekenbrink, R G H, Voskuil, M, and Vliegen, H W

Published
2021

15. De Gouden Eeuw meebeleefd door zeeschilders.

Author

Wagenaar, L. J.

Subjects
DUTCH marine painting, NONFICTION
Abstract

The article reviews the book "Opkomst en ondergang van Nederlands gouden vloot. Door de ogen van de zeeschilders Willem van de Velde de Oude en de Jonge" by Ronald Prud'homme van Reine, from the series "Arbeiderspers."

Published
2009
Full Text
View/download PDF

16. Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC)

Author

Csilla Liptai, Werner Budts, Silvana Jovanova, Jolien W Roos-Hesselink, Mark R. Johnson, David Majdalany, Mohamad Gamal Abd-El Aziz, Aldo P. Maggioni, Roger Hall, Oktay Tutarel, Lucia Baris, Heidi M Connolly, Alexandra Frogoudaki, Cardiology, University of Zurich, Roos-Hesselink, Jolien W, Gale, Christopher Peter, Beleslin, Branko, Budaj, Andrzej, Chioncel, Ovidiu, Dagres, Nikolaos, Danchin, Nicolas, Erlinge, David, Emberson, Jonathan, Glikson, Michael, Gray, Alastair, Kayikcioglu, Meral, Maggioni, Aldo, Nagy, Klaudia Vivien, Nedoshivin, Aleksandr, Petronio, Anna-Sonia, Roos-Hesselink, Jolien, Wallentin, Lars, Zeymer, Uwe, Hall, Roger, Stein, Joerg, Parsonage, William Anthony, Budts, Werner, Backer, Julie De, Grewal, Jasmin, Kaemmerer, Harald, Marelli, Ariane, Jondeau, Guillaume, Johnson, Mark, Maggioni, Aldo P, Tavazzi, Luigi, Thilen, Ulf, Elkayam, Uri, Otto, Catherine, Sliwa, Karen, Aquieri, A, Saad, A, Ruda Vega, H, Hojman, J, Caparros, J M, Vazquez Blanco, M, Arstall, M, Chung, C M, Mahadavan, G, Aldridge, E, Wittwer, M, Chow, Y Y, Parsonage, W A, Lust, K, Collins, N, Warner, G, Hatton, R, Gordon, A, Nyman, E, Stein, J, Donhauser, E, Gabriel, H, Bahshaliyev, A, Guliyev, F, Hasanova, I, Jahangirov, T, Gasimov, Z, Salim, A, Ahmed, C M, Begum, F, Hoque, M H, Mahmood, M, Islam, M N, Haque, P P, Banerjee, S K, Parveen, T, Morissens, M, De Backer, J, Demulier, L, de Hosson, M, Budts, W, Beckx, M, Kozic, M, Lovric, M, Kovacevic-Preradovic, T, Chilingirova, N, Kratunkov, P, McLean, S, Gordon, E, Walter, L, Marelli, A, Montesclaros, A R, Monsalve, G, Rodriguez, C, Balthazar, F, Quintero, V, Palacio, W, Mejía Cadavid, L A, Munoz Ortiz, E, Fortich Hoyos, F, Arevalo Guerrero, E, Gandara Ricardo, J, Velasquez Penagos, J, Vavera, Z, Popelova, J, Vejlstrup, N, Grønbeck, L, Johansen, M, Ersboll, A, Elrakshy, Y, Eltamawy, K, Gamal Abd-El Aziz, M, El Nagar, A, Ebaid, H, Abo Elenin, H, Saed, M, Farag, S, Makled, W, Sorour, K, Ashour, Z, El-Sayed, G, Abdel Meguid Mahdy, M, Taha, N, Dardeer, A, Shabaan, M, Ali, M, Moceri, P, Duthoit, G, Gouton, M, Nizard, J, Baris, L, Cohen, S, Ladouceur, M, Khimoud, D, Iung, B, Berger, F, Olsson, A, Gembruch, U, Merz, W M, Reinert, E, Clade, S, Kliesch, Y, Wald, C, Sinning, C, Kozlik-Feldmann, R, Blankenberg, S, Zengin-Sahm, E, Mueller, G, Hillebrand, M, Hauck, P, von Kodolitsch, Y, Zarniko, N, Baumgartner, H, Hellige, A, Tutarel, O, Kaemmerer, H, Kuschel, B, Nagdyman, N, Motz, R, Maisuradze, D, Frogoudaki, A, Iliodromitis, E, Anastasiou-Nana, M, Marousi, D, Triantafyllis, G, Bekiaris, H Karvounis, Giannakoulas, G, Ntiloudi, D, Mouratoglou, S A, Temesvari, A, Balint, H, Kohalmi, D, Merkely, B, Liptai, C, Nemes, A, Forster, T, Kalapos, A, Berek, K, Havasi, K, Ambrus, N, Shelke, A, Kawade, R, Patil, S, Martanto, E, Aprami, T M, Purnomowati, A, Cool, C J, Hasan, M, Akbar, R, Hidayat, S, Dewi, T I, Permadi, W, Soedarsono, D A, Ansari-Ramandi, M M, Samiei, N, Tabib, A, Kashfi, F, Ansari-Ramandi, S, Rezaei, S, Ali Farhan, H, Al-Hussein, A, Al-Saedi, G, Mahmood, G, Yaseen, I F, Al-Yousuf, L, AlBayati, M, Mahmood, S, Raheem, S, AlHaidari, T, Dakhil, Z, Thornton, P, Donnelly, J, Bowen, M, Blatt, A, Elbaz-Greener, G, Shotan, A, Yalonetsky, S, Goland, S, Biener, M, Egidy Assenza, G, Bonvicini, M, Donti, A, Bulgarelli, A, Prandstraller, D, Romeo, C, Crepaz, R, Sciatti, E, Metra, M, Orabona, R, Ait Ali, L, Festa, P, Fesslova, V, Bonanomi, C, Calcagnino, M, Lombardi, F, Colli, A M, Ossola, M W, Gobbi, C, Gherbesi, E, Tondi, L, Schiavone, M, Squillace, M, Carmina, M G, Maina, A, Macchi, C, Gollo, E, Comoglio, F M, Montali, N, Re, P, Bordese, R, Todros, T, Donvito, V, Grosso Marra, W, Sinagra, G, D'Agata Mottolese, B, Bobbo, M, Gesuete, V, Rakar, S, Ramani, F, Niwa, K, Mekebekova, D, Mussagaliyeva, A, Lee, T, Mirrakhimov, E, Abilova, S, Bektasheva, E, Neronova, K, Lunegova, O, Žaliūnas, Remigijus, Jonkaitienė, Regina, Petrauskaitė, J, Laucevičius, Aleksandras, Žebrauskienė, Dovilė, Laučiuvienė, L, Gumbienė, Lina, Lankutienė, L, Glaveckaitė, Sigita, Laukytė, M, Solovjova, Svetlana, Rudienė, Virginija, Chee, K H, C C-W, Yim, Ang, H L, Kuppusamy, R, Watson, T, Caruana, M, Estensen, M-E, Mahmood Kayani, M G A, Munir, R, Tomaszuk-Kazberuk, A, Sobkowicz, B, Przepiesc, J, Lesniak-Sobelga, A, Tomkiewicz-Pajak, L, Komar, M, Olszowska, M, Podolec, P, Wisniowska-Smialek, S, Lelonek, M, Faflik, U, CichockaRadwan, A, Plaskota, K, Trojnarska, O, Guerra, N, de Sousa, L, Cruz, C, Ribeiro, V, Jovanova, S, Petrescu, V, Jurcut, R, Ginghina, C, Mircea Coman, I, Musteata, M, Osipova, O, Golivets, T, Khamnagadaev, I, Golovchenko, O, Nagibina, A, Ropatko, I, Gaisin, I R, Valeryevna Shilina, L, Sharashkina, N, Shlyakhto, E, Irtyuga, O, Moiseeva, O, Karelkina, E, Zazerskaya, I, Kozlenok, A, Sukhova, I, Jovovic, L, Prokšelj, K, Koželj, M, Askar, A O, Abdilaahi, A A, Mohamed, M H, Dirir, A M, Sliwa, K, Manga, P, Pijuan-Domenech, A, Galian-Gay, L, Tornos, P, Subirana, M T, Murga, N, Oliver, J M, Garcia-Aranda Dominguez, B, Hernandez Gonzalez, I, Delgado Jimenez, J F, Escribano Subias, P, Elbushi, A, Suliman, A, Jazzar, K, Murtada, M, Ahamed, N, Dellborg, M, Furenas, E, Jinesjo, M, Skoglund, K, Eriksson, P, Gilljam, T, Thilen, U, Tobler, D, Wustmann, K, Schwitz, F, Rutz, T, Bouchardy, J, Greutmann, M, Santos Lopes, B M, Meier, L, Arrigo, M, de Boer, K, Konings, T, Wagenaar, L J, Polak, P, Pieper, E Pg, RoosHesselink, J, van Hagen, I, Duvekot, H, Cornette, J M J, De Groot, C, van Oppen, C, Sarac, L, Batukan Esen, O, Catirli Enar, S, Mondo, C, Ingabire, P, Nalwanga, B, Semu, T, Salih, B T, Almahmeed, W A R, Wani, S, Mohamed Farook, F S, Al Ain, F, Gerges, A M, Komaranchath, F, Al Bakshi, A, Al Mulla, A H, Yusufali, E I, Al Hatou, N, Bazargani, F, Hussain, L, Hudsmith, P, Thompson, S, Thorne, S, Bowater, A, Money-Kyrle, P, Clifford, P, Ramrakha, S Firoozan, Chaplin, J, Bowers, N, Adamson, D, Schroeder, F, Wendler, R, Hammond, S, Nihoyannopoulos, P, Hall, R, Freeman, L, Kerr, J, Tellett, L, Scott, N, Bhatt, A B, DeFaria Yeh, D, Youniss, M A, Wood, M, Sarma, A A, Tsiaras, S, Stefanescu, A, Duran, J M, Stone, L, Majdalany, D S, Chapa, J, Chintala, K, Gupta, P, Botti, J, Ting, J, Davidson, W R, Wells, G, Sparks, D, Paruchuri, V, Marzo, K, Patel, D, Wagner, W, Ahanya, S N, Colicchia, L, Jentink, T, Han, K, Loichinger, M, Parker, M, Longtin, C, Yetman, A, Erickson, K, Cramer, J, Tsai, S, Fletcher, B, Warta, S, Cohen, C, Lindblade, C, Puntel, R, Nagaran, K, Croft, N, Gurvitz, M, Otto, C, Talluto, C, Murphy, D, Perlroth, M G, and Jančauskaitė, Dovilė

Subjects
Male, Cardiac & Cardiovascular Systems, Ventricular Dysfunction, Right, 030204 cardiovascular system & hematology, ATRIAL REPAIR, 0302 clinical medicine, Pregnancy, CONGENITALLY CORRECTED TRANSPOSITION, Registries, Aortic dissection, RISK, 030219 obstetrics & reproductive medicine, Ejection fraction, MUSTARD OPERATION, Congenital Heart Disease, Pregnancy Outcome, Arteries, pregnancy, transposition of great vessels, EUROPEAN-SOCIETY, ddc, Great arteries, Cardiology, 10209 Clinic for Cardiology, cardiovascular system, Maternal death, Female, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, Heart Ventricles, 610 Medicine & health, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, Young Adult, INTERNATIONAL-SOCIETY, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Endocarditis, Humans, cardiovascular diseases, Heart Failure, Science & Technology, business.industry, Arrhythmias, Cardiac, medicine.disease, Heart failure, Cardiovascular System & Cardiology, business, Mace
Abstract

ObjectiveCardiac disease is a major cause of maternal mortality. Data regarding pregnancy outcomes in women with a systemic right ventricle (sRV) are scarce. We studied pregnancy outcomes in women with an sRV after the atrial switch procedure for transposition of the great arteries (TGA) or congenitally corrected TGA (CCTGA).MethodsThe ESC EORP Registry of Pregnancy and Cardiac Disease is an international prospective registry of pregnant women with cardiac disease. Pregnancy outcomes (maternal/fetal) in all women with an sRV are described. The primary end point was a major adverse cardiac event (MACE) defined as maternal death, supraventricular or ventricular arrhythmias requiring treatment, heart failure, aortic dissection, endocarditis, ischaemic coronary event and other thromboembolic events.ResultsAltogether, 162 women with an sRV (TGA n=121, CCTGA n=41, mean age 28.8±4.6 years) were included. No maternal mortality occurred. In 26 women, at least one MACE occurred, heart failure in 16 (9.8%), arrhythmias (atrial 5, ventricular 6) in 11 (6.7%) and others in 4 (2.5%). Prepregnancy signs of heart failure as well as an sRV ejection fraction ConclusionThe majority of women with an sRV tolerated pregnancy well with a favourable maternal and fetal outcome. Heart failure and arrhythmias were the most common MACE.

Published
2022

17. Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease

Author

Jasmine Grewal, Lucia Baris, Jolien W Roos-Hesselink, Julie De Backer, Laurence Campens, Guillaume Jondeau, Antione Bondue, Mark R. Johnson, Craig S. Broberg, Nandita S. Scott, Roger Hall, Cardiology, Aquieri, A., Saad, A., Ruda Vega, H., Hojman, J., Caparros, J M, Vazquez Blanco, M., Arstall, M., Chung, C M, Mahadavan, G., Aldridge, E., Wittwer, M., Chow, Y Y, Parsonage, W A, Lust, K., Collins, N., Warner, G., Hatton, R., Gordon, A., Nyman, E., Stein, J., Donhauser, E., Gabriel, H., Bahshaliyev, A., Guliyev, F., Hasanova, I., Jahangirov, T., Gasimov, Z., Salim, A., Ahmed, C M, Begum, F., Mahmood, M., Islam, M N, Haque, P P, Banerjee, S K, Parveen, T., Morissens, M., De Backer, J., Demulier, L., de Hosson, M., Budts, W., Beckx, M., Kozic, M., Lovric, M., Kovacevic-Preradovic, T., Chilingirova, N., Kratunkov, P., Wahab, N., Gordon, E., Walter, L., Marelli, A., Montesclaros, A R, Monsalve, G., Rodriguez, C., Balthazar, F., Quintero, V., Palacio, W., Mejía Cadavid, L A, Munoz Ortiz, E., Fortich Hoyos, F., Arevalo Guerrero, E., Gandara Ricardo, J., Velasquez Penagos, J., Vavera, Z., Popelova, J., Vejlstrup, N., Grønbeck, L., Johansen, M., Ersboll, A., Elrakshy, Y., Eltamawy, K., Gamal Abd-El Aziz, M., El Nagar, A., Ebaid, H., Abo Elenin, H., Saed, M., Farag, S., Makled, W., Sorour, K., Ashour, Z., El-Sayed, G., Abdel Meguid Mahdy, M., Taha, N., Dardeer, A., Shabaan, M., Ali, M., Moceri, P., Duthoit, G., Gouton, M., Nizard, J., Baris, L., Cohen, S., Ladouceur, M., Khimoud, D., Iung, B., Berger, F., Olsson, A., Gembruch, U., Merz, W M, Reinert, E., Clade, S., Kliesch, Y., Sinning, C., Kozlik-Feldmann, R., Blankenberg, S., Zengin-Sahm, E., Mueller, G., Hillebrand, M., Hauck, P., von Kodolitsch, Y., Zarniko, N., Baumgartner, H., Hellige, A., Tutarel, O., Kaemmerer, H., Kuschel, B., Motz, R., Maisuradze, D., Frogoudaki, A., Iliodromitis, E., Anastasiou-Nana, M., Marousi, D., Triantafyllis, G., Bekiaris, H., Karvounis, G., Giannakoulas, D., Ntiloudi, S A, Mouratoglou, A., Temesvari, H Balint, Kohalmi, D., Merkely, B., Liptai, C., Nemes, A., Forster, T., Kalapos, A., Berek, K., Havasi, K., Ambrus, N., Shelke, A., Patil, S., Martanto, E., Aprami, T M, Purnomowati, A., Cool, C J, Hasan, M., Akbar, R., Hidayat, S., Dewi, T I, Permadi, W., Soedarsono, D A, Ansari-Ramandi, M M, Samiei, N., Tabib, A., Kashfi, F., Ansari-Ramandi, S., Rezaei, S., Ali Farhan, H., Al-Hussein, A., Al-Saedi, G., Mahmood, G., Yaseen, I F, Al-Yousuf, L., AlBayati, M., Mahmood, S., Raheem, S., AlHaidari, T., Dakhil, Z., Thornton, P., Donnelly, J., Bowen, M., Blatt, A., Elbaz-Greener, G., Shotan, A., Yalonetsky, S., Goland, S., Biener, M., Egidy Assenza, G., Bonvicini, M., Donti, A., Bulgarelli, A., Prandstraller, D., Romeo, C., Crepaz, R., Sciatti, E., Metra, M., Orabona, R., Ait Ali, L., Festa, P., Fesslova, V., Bonanomi, C., Calcagnino, M., Lombardi, F., Colli, A M, Ossola, M W, Gobbi, C., Gherbesi, E., Tondi, L., Schiavone, M., Squillace, M., Carmina, M G, Maina, A., Macchi, C., Gollo, E., Comoglio, F M, Montali, N., Re, P., Bordese, R., Todros, T., Donvito, V., Grosso Marra, W., Sinagra, G., D'Agata Mottolese, B., Bobbo, M., Gesuete, V., Rakar, S., Ramani, F., Niwa, K., Mekebekova, D., Mussagaliyeva, A., Lee, T., Mirrakhimov, E., Abilova, S., Bektasheva, E., Neronova, K., Lunegova, O., Žaliūnas, R., Jonkaitienė, R., Petrauskaitė, J., Laucevičius, Aleksandras, Žebrauskienė, Dovilė, Laučiuvienė, Laimutė, Gumbienė, Lina, Lankutienė, Lina, Glaveckaitė, Sigita, Laukytė, Monika, Solovjova, Svetlana, Rudienė, Virginija, C C-W, Yim, Ang, H L, Kuppusamy, R., Watson, T., Caruana, M., Estensen, M-E, Mahmood Kayani, M G A, Munir, R., Sobkowicz, B., Przepiesc, J., Lesniak-Sobelga, A., Tomkiewicz-Pajak, L., Komar, M., Olszowska, M., Podolec, P., Wisniowska-Smialek, S., Lelonek, M., Faflik, U., Cichocka-Radwan, A., Plaskota, K., Trojnarska, O., de Sousa, L., Cruz, C., Ribeiro, V., Jovanova, S., Petrescu, V., Jurcut, R., Ginghina, C., Mircea Coman, I., Musteata, M., Osipova, O., Golivets, T., Khamnagadaev, I., Golovchenko, O., Nagibina, A., Ropatko, I., Gaisin, I R, Valeryevna Shilina, L., Sharashkina, N., Shlyakhto, E., Irtyuga, O., Moiseeva, O., Karelkina, E., Zazerskaya, I., Kozlenok, A., Sukhova, I., Jovovic, L., Prokšelj, K., Koželj, M., Askar, A O, Abdilaahi, A A, Mohamed, M H, Sliwa, K., Manga, P., Galian-Gay, L., Tornos, P., Subirana, M T, Murga, N., Oliver, J M, Garcia-Aranda Dominguez, B., Hernandez Gonzalez, I., Escribano Subias, P., Elbushi, A., Suliman, A., Jazzar, K., Murtada, M., Ahamed, N., Dellborg, M., Furenas, E., Jinesjo, M., Skoglund, K., Eriksson, P., Gilljam, T., Thilen, U., Tobler, D., Wustmann, K., Schwitz, F., Schwerzmann, M., Rutz, T., Bouchardy, J., Greutmann, M., Santos Lopes, B M, Meier, L., Arrigo, M., de Boer, K., Konings, T., Wajon, E., Wagenaar, L J, Polak, P., Pieper, E Pg, Roos-Hesselink, J., van Hagen, I., Duvekot, H., Cornette, J M J, De Groot, C., van Oppen, C., Sarac, L., Batukan Esen, O., Catirli Enar, S., Mondo, C., Ingabire, P., Nalwanga, B., Semu, T., Salih, B T, Almahmeed, W A R, Wani, S., Mohamed Farook, F S, Al Ain, F Gerges, Gerges, F., Komaranchath, A M, Al Bakshi, F., Al Mulla, A., Yusufali, A H, Al Hatou, E I, Bazargani, N., Hussain, F., Hudsmith, L., Thompson, P., Thorne, S., Bowater, S., Money-Kyrle, A., Clifford, P., Ramrakha, P., Firoozan, S., Chaplin, J., Bowers, N., Adamson, D., Schroeder, F., Wendler, R., Nihoyannopoulos, P., Hall, R., Freeman, L., Veldtman, G., Kerr, J., Tellett, L., Scott, N., Bhatt, A B, DeFaria Yeh, D., Youniss, M A, Wood, M., Sarma, A A, Tsiaras, S., Stefanescu, A., Duran, J M, Stone, L., Majdalany, D S, Chapa, J., Chintala, K., Gupta, P., Botti, J., Ting, J., Davidson, W R, Wells, G., Sparks, D., Paruchuri, V., Marzo, K., Patel, D., Wagner, W., Ahanya, S N, Colicchia, L., Jentink, T., Han, K., Loichinger, M., Parker, M., Longtin, C., Yetman, A., Erickson, K., Tsai, S., Fletcher, B., Warta, S., Cohen, C., Lindblade, C., Puntel, R., Nagaran, K., Croft, N., Gurvitz, M., Otto, C., Talluto, C., Murphy, D., Perlroth, M G, and Jančauskaitė, Dovilė

Subjects
Marfan syndrome, Heart malformation, Aorta, Thoracic, Comorbidity, 030204 cardiovascular system & hematology, Global Health, Aortic aneurysm, 0302 clinical medicine, Bicuspid aortic valve, Pregnancy, Cause of Death, Turner syndrome, Medicine and Health Sciences, Prospective Studies, Registries, DISSECTION, Cause of death, Aortic dissection, 030219 obstetrics & reproductive medicine, Incidence, Pregnancy Outcome, WOMEN, Aortic and Vascular Disease, MARFAN-SYNDROME, Survival Rate, Marfan and associated disorders, aortic and arterial disease, aortic aneurysm, bicuspid aortic valve, pregnancy, Cardiology, cardiovascular system, Female, Cardiology and Cardiovascular Medicine, Adult, medicine.medical_specialty, Heart Diseases, Pregnancy Complications, Cardiovascular, Aortic Diseases, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, business.industry, Infant, Newborn, medicine.disease, business
Abstract

BackgroundCardiovascular disease is the leading cause of death during pregnancy with thoracic aortic dissection being one of the main causes. Thoracic aortic disease is commonly related to hereditary disorders and congenital heart malformations such as bicuspid aortic valve (BAV). Pregnancy is considered a high risk period in women with underlying aortopathy.MethodsThe ESC EORP Registry Of Pregnancy And Cardiac disease (ROPAC) is a prospective global registry that enrolled 5739 women with pre-existing cardiac disease. With this analysis, we aim to study the maternal and fetal outcome of pregnancy in women with thoracic aortic disease.ResultsThoracic aortic disease was reported in 189 women (3.3%). Half of them were patients with Marfan syndrome (MFS), 26% had a BAV, 8% Turner syndrome, 2% vascular Ehlers-Danlos syndrome and 11% had no underlying genetic defect or associated congenital heart defect. Aortic dilatation was reported in 58% of patients and 6% had a history of aortic dissection. Four patients, of whom three were patients with MFS, had an acute aortic dissection (three type A and one type B aortic dissection) without maternal or fetal mortality. No complications occurred in women with a history of aortic dissection. There was no significant difference in median fetal birth weight if treated with a beta-blocker or not (2960 g (2358–3390 g) vs 3270 g (2750–3570 g), p value 0.25).ConclusionThis ancillary analysis provides the largest prospective data review on pregnancy risk for patients with thoracic aortic disease. Overall pregnancy outcomes in women with thoracic aortic disease followed according to current guidelines are good.

Published
2021

19. Non-intubated recovery from refractory cardiogenic shock on percutaneous VA-extracorporeal membrane oxygenation.

Author

van Houte J, Donker DW, Wagenaar LJ, Slootweg AP, Kirkels JH, and van Dijk D

Abstract

We report on the use of percutaneous femoral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in a fully awake, non-intubated and spontaneously breathing patient suffering from acute, severe and refractory cardiogenic shock due to a (sub)acute anterior myocardial infarction. Intensified heart failure therapy was closely monitored with a pulmonary artery catheter and allowed gradual weaning off the ECMO support without additional invasive measures, notably without mechanical ventilation. Neurological assessment was possible at all times and complete physical mobilisation was straightforward directly after weaning from ECMO. This limited invasive approach may encourage a more widespread use of percutaneous VA-ECMO.

Published
2015
Full Text
View/download PDF

20. Heart failure admissions in adults with congenital heart disease; risk factors and prognosis.

Author

Zomer AC, Vaartjes I, van der Velde ET, de Jong HM, Konings TC, Wagenaar LJ, Heesen WF, Eerens F, Baur LH, Grobbee DE, and Mulder BJ

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Risk Assessment, Risk Factors, Young Adult, Heart Defects, Congenital complications, Heart Failure etiology, Heart Failure mortality, Patient Admission statistics & numerical data
Abstract

Background: Heart failure (HF) is a serious complication and often the cause of death in adults with congenital heart disease (CHD). Therefore, our aims were to determine the frequency of HF-admissions, and to assess risk factors of first HF-admission and of mortality after first HF-admission in adults with CHD., Methods: The Dutch CONCOR registry was linked to the Hospital Discharge Registry and National Mortality Registry to obtain data on HF-admissions and mortality. Risk factors for both HF-admission and mortality were assessed using Cox regression models., Results: Of 10,808 adult patients (49% male), 274 (2.5%) were admitted for HF during a median follow-up period of 21 years. The incidence of first HF-admission was 1.2 per 1000 patient-years, but the incidence of HF itself will be higher. Main defect, multiple defects, and surgical interventions in childhood were identified as independent risk factors of HF-admission. Patients admitted for HF had a five-fold higher risk of mortality than patients not admitted (hazard ratio (HR)=5.3; 95% confidence interval 4.2-6.9). One- and three-year mortality after first HF-admission were 24% and 35% respectively. Independent risk factors for three-year mortality after first HF-admission were male gender, pacemaker implantation, admission duration, non-cardiac medication use and high serum creatinine., Conclusions: The incidence of HF-admission in adults with CHD is 1.2 per 1000 patient-years. Mortality risk is substantially increased after HF-admission, which emphasises the importance to identify patients at high risk of HF-admission. These patients might benefit from closer follow-up and earlier medical interventions. The presented risk factors may facilitate surveillance., (Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.)

Published
2013
Full Text
View/download PDF

21. Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease.

Author

van de Wal RM, van der Harst P, Wagenaar LJ, Wassmann S, Morshuis WJ, Nickenig G, Buikema H, Plokker HW, van Veldhuisen DJ, van Gilst WH, and Voors AA

Subjects
Acetylcholine pharmacology, Adrenergic alpha-Antagonists pharmacology, Adult, Aged, Aged, 80 and over, Angiotensin II pharmacology, Angiotensin II Type 1 Receptor Blockers pharmacology, Benzimidazoles pharmacology, Biphenyl Compounds, Female, Gene Expression drug effects, Humans, Imidazoles pharmacology, In Vitro Techniques, Male, Mammary Arteries drug effects, Middle Aged, Oligopeptides pharmacology, Phentolamine pharmacology, Phenylephrine pharmacology, Pyridines pharmacology, Receptor, Angiotensin, Type 1 genetics, Receptor, Angiotensin, Type 1 metabolism, Receptor, Angiotensin, Type 1 physiology, Receptor, Angiotensin, Type 2 genetics, Receptor, Angiotensin, Type 2 metabolism, Sodium Nitrite pharmacology, Tetrazoles pharmacology, Vasoconstrictor Agents pharmacology, Vasodilation drug effects, Vasodilator Agents pharmacology, Coronary Artery Disease physiopathology, Mammary Arteries physiology, Receptor, Angiotensin, Type 2 physiology, Vasodilation physiology
Abstract

Background: Several animal studies suggested that the angiotensin II type 2 (AT2) receptor subtype mediates vasodilation, yet the results in human arteries are less well described and more inconsistent. Therefore, we evaluated the role of the AT2 receptor stimulation on the vasotonus of human internal mammary arteries., Methods: Internal mammary arteries were obtained from 50 patients undergoing coronary bypass surgery. The expression of angiotensin II type 1 (AT1) receptor and AT2 receptor mRNA was determined by using real-time polymerase chain reaction. In addition, angiotensin II and CGP42112A concentration-response curves (concentration range: 10(-10) M to 10(-6) M) were constructed in absence or presence of candesartan (10(-5) M) and/or the AT2 receptor-antagonist PD-123319 (10(-6) M) and/or the alpha receptor antagonist phentolamine., Results: Both AT1 and AT2 receptor protein and mRNA were detected, and higher AT2 receptor mRNA expression levels were associated with increased contractile response to angiotensin II. Angiotensin II caused vasoconstriction up to 41.1 +/- 6.5% of the maximal response to phenylephrine, and PD123319 significantly reduced this response (28.6 +/- 9.6%, P < 0.001). Candesartan completely blocked the angiotensin II-mediated response (1.4 +/- 3.1%, P < 0.001 versus control), and additional blockade of the AT2 receptor with PD123319 did not change this effect (1.8 +/- 5.1%). Phentolamine (10(-5) M) caused attenuation and rightward shift of the angiotensin II concentration response curves. The AT2 receptor agonist CGP42112A did not induce a significant response., Conclusion: Although AT2 receptor mRNA is present in human internal mammary arteries, AT2 receptor stimulation does not mediate vasodilation in these arteries.

Published
2007
Full Text
View/download PDF

22. Pre-procedural ACE-activity does not predict symptomatic in-stent restenosis.

Author

Wagenaar LJ, Rahel BM, van Boven AJ, Voors AA, van der Wal AC, Plokker HW, and van Gilst WH

Subjects
Atherectomy, Coronary, Biomarkers metabolism, Biopsy, Coronary Restenosis surgery, Coronary Stenosis enzymology, Coronary Vessels pathology, Female, Follow-Up Studies, Humans, Immunohistochemistry, Male, Middle Aged, Prognosis, Prosthesis Failure, Retrospective Studies, Severity of Illness Index, Time Factors, Angioplasty, Balloon, Coronary instrumentation, Coronary Restenosis enzymology, Coronary Stenosis therapy, Coronary Vessels enzymology, Peptidyl-Dipeptidase A metabolism, Stents
Abstract

Background: Several studies indicate that ACE-activity is related to atherosclerosis. We investigated the correlation between ACE-activity, in plasma as well as in the atherosclerotic plaque, and in-stent restenosis., Methods and Results: ACE-activity was measured in blood samples from 178 patients who underwent a percutaneous coronary intervention with stent placement. During 8 months follow-up, 51 of these patients had an adverse clinical event. ACE-activity did not differ between patients with or without adverse events (21.5 vs. 23.1 nM/ml/min; P=0.36). Tissue samples were obtained with an atherectomy catheter before elective stent placement in another group of 13 patients with de novo stenosis. In this tissue, we determined the ACE-content immunohistologically. These patients were scheduled for follow-up quantitative coronary angiography after 12 months. In this group, the quantity of ACE was not correlated to the late luminal loss (0.31 vs. 0.38 mm; P=0.76)., Conclusion: In this study, pre-procedural ACE-activity, in plasma as well as in the atherosclerotic plaque, does not predict the occurrence of in-stent restenosis.

Published
2005
Full Text
View/download PDF

24. Troglitazone. Is it all over?

Author

Wagenaar LJ, Kuck EM, and Hoekstra JB

Subjects
Animals, Blood Glucose drug effects, Chemical and Drug Induced Liver Injury, Chromans adverse effects, Drug Therapy, Combination, Female, Humans, Hypertriglyceridemia drug therapy, Hypoglycemic Agents adverse effects, Insulin Resistance, Liver Function Tests, Male, Thiazoles adverse effects, Troglitazone, Chromans pharmacology, Chromans therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use, Thiazoles pharmacology, Thiazoles therapeutic use, Thiazolidinediones
Abstract

In January 1997 a drug from a new pharmacological class, the thiazolidinediones, became available: troglitazone. Troglitazone indirectly enhances peripheral insulin sensitivity. In this way it lowers the levels of both glucose and insulin. Troglitazone also has a lowering effect on the levels of triglycerides. In clinical trials only mild side effects had been observed. Therefore, troglitazone seemed a promising drug. Recently, however, it became clear that troglitazone could cause liver dysfunction in some patients. Although this side effect is reversible in most cases, six deaths have been described due to liver damage. Troglitazone was to be introduced in Europe in 1998 but registration procedures and clinical trials have been stopped because of its side effects on the liver. In the United States and Japan troglitazone is still being used, albeit with extra precautions. Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes. It can be particularly useful, both as an additive and as a replacement, in patients for whom metformin is not suitable because of contraindications or side effects. The risk of severe liver dysfunction is a reason to reserve troglitazone as a second-line drug.

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results